Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
718 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Colorectal Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Metastatic Colorectal Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Colorectal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer - The report reviews pipeline therapeutics for Metastatic Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Colorectal Cancer therapeutics and enlists all their major and minor projects - The report assesses Metastatic Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 7 Metastatic Colorectal Cancer Overview 8 Therapeutics Development 9 Metastatic Colorectal Cancer - Therapeutics under Development by Companies 11 Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 17 Metastatic Colorectal Cancer - Pipeline Products Glance 18 Metastatic Colorectal Cancer - Products under Development by Companies 22 Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 30 Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 31 Metastatic Colorectal Cancer - Therapeutics Assessment 115 Drug Profiles 140 Metastatic Colorectal Cancer - Recent Pipeline Updates 436 Metastatic Colorectal Cancer - Dormant Projects 681 Metastatic Colorectal Cancer - Discontinued Products 690 Metastatic Colorectal Cancer - Product Development Milestones 693 Appendix 702
List of Tables
Number of Products under Development for Metastatic Colorectal Cancer, H1 2016 24 Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016 25 Number of Products under Development by Companies, H1 2016 26 Number of Products under Development by Companies, H1 2016 (Contd..1) 27 Number of Products under Development by Companies, H1 2016 (Contd..2) 28 Number of Products under Development by Companies, H1 2016 (Contd..3) 29 Number of Products under Development by Companies, H1 2016 (Contd..4) 30 Number of Products under Development by Companies, H1 2016 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H1 2016 32 Comparative Analysis by Late Stage Development, H1 2016 33 Comparative Analysis by Clinical Stage Development, H1 2016 34 Comparative Analysis by Early Stage Development, H1 2016 35 Comparative Analysis by Unknown Stage Development, H1 2016 36 Products under Development by Companies, H1 2016 37 Products under Development by Companies, H1 2016 (Contd..1) 38 Products under Development by Companies, H1 2016 (Contd..2) 39 Products under Development by Companies, H1 2016 (Contd..3) 40 Products under Development by Companies, H1 2016 (Contd..4) 41 Products under Development by Companies, H1 2016 (Contd..5) 42 Products under Development by Companies, H1 2016 (Contd..6) 43 Products under Development by Companies, H1 2016 (Contd..7) 44 Products under Investigation by Universities/Institutes, H1 2016 45 Metastatic Colorectal Cancer - Pipeline by AB Science SA, H1 2016 46 Metastatic Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016 47 Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 48 Metastatic Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 49 Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016 50 Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H1 2016 51 Metastatic Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016 52 Metastatic Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016 53 Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016 54 Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 55 Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016 56 Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 57 Metastatic Colorectal Cancer - Pipeline by Baxalta Incorporated, H1 2016 58 Metastatic Colorectal Cancer - Pipeline by Bayer AG, H1 2016 59 Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H1 2016 60 Metastatic Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016 61 Metastatic Colorectal Cancer - Pipeline by Bionovis SA, H1 2016 62 Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 63 Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 64 Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016 65 Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016 66 Metastatic Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016 67 Metastatic Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016 68 Metastatic Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 69 Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 70 Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016 71 Metastatic Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 72 Metastatic Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016 73 Metastatic Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016 74 Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2016 75 Metastatic Colorectal Cancer - Pipeline by EnGeneIC Ltd, H1 2016 76 Metastatic Colorectal Cancer - Pipeline by Etubics Corporation, H1 2016 77 Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H1 2016 78 Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 79 Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 80 Metastatic Colorectal Cancer - Pipeline by Gilead Sciences, Inc., H1 2016 81 Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H1 2016 82 Metastatic Colorectal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2016 83 Metastatic Colorectal Cancer - Pipeline by Hetero Drugs Limited, H1 2016 84 Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 85 Metastatic Colorectal Cancer - Pipeline by Ignyta, Inc., H1 2016 86 Metastatic Colorectal Cancer - Pipeline by Immatics Biotechnologies GmbH, H1 2016 87 Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2016 88 Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2016 89 Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016 90 Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 91 Metastatic Colorectal Cancer - Pipeline by Mabion SA, H1 2016 92 Metastatic Colorectal Cancer - Pipeline by Mabtech Limited, H1 2016 93 Metastatic Colorectal Cancer - Pipeline by mAbxience S.A., H1 2016 94 Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H1 2016 95 Metastatic Colorectal Cancer - Pipeline by MedImmune, LLC, H1 2016 96 Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2016 97 Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H1 2016 98 Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 99 Metastatic Colorectal Cancer - Pipeline by Merus B.V., H1 2016 100 Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 101 Metastatic Colorectal Cancer - Pipeline by Mologen AG, H1 2016 102 Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2016 103 Metastatic Colorectal Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 104 Metastatic Colorectal Cancer - Pipeline by Natco Pharma Limited, H1 2016 105 Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H1 2016 106 Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 107 Metastatic Colorectal Cancer - Pipeline by Novartis AG, H1 2016 108 Metastatic Colorectal Cancer - Pipeline by OBI Pharma, Inc., H1 2016 109 Metastatic Colorectal Cancer - Pipeline by Oncobiologics, Inc., H1 2016 110 Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 111 Metastatic Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 112 Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2016 113 Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H1 2016 114 Metastatic Colorectal Cancer - Pipeline by Pharma Mar, S.A., H1 2016 115 Metastatic Colorectal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 116 Metastatic Colorectal Cancer - Pipeline by Precision Biologics, Inc., H1 2016 117 Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016 118 Metastatic Colorectal Cancer - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016 119 Metastatic Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 120 Metastatic Colorectal Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016 121 Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H1 2016 122 Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 123 Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 124 Metastatic Colorectal Cancer - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 125 Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016 126 Metastatic Colorectal Cancer - Pipeline by Tocagen Inc., H1 2016 127 Metastatic Colorectal Cancer - Pipeline by Vaximm AG, H1 2016 128 Metastatic Colorectal Cancer - Pipeline by XBiotech USA, Inc., H1 2016 129 Assessment by Monotherapy Products, H1 2016 130 Assessment by Combination Products, H1 2016 131 Number of Products by Stage and Target, H1 2016 133 Number of Products by Stage and Mechanism of Action, H1 2016 144 Number of Products by Stage and Route of Administration, H1 2016 152 Number of Products by Stage and Molecule Type, H1 2016 154 Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 451 Metastatic Colorectal Cancer - Dormant Projects, H1 2016 697 Metastatic Colorectal Cancer - Dormant Projects (Contd..1), H1 2016 698 Metastatic Colorectal Cancer - Dormant Projects (Contd..2), H1 2016 699 Metastatic Colorectal Cancer - Dormant Projects (Contd..3), H1 2016 700 Metastatic Colorectal Cancer - Dormant Projects (Contd..4), H1 2016 701 Metastatic Colorectal Cancer - Dormant Projects (Contd..5), H1 2016 702 Metastatic Colorectal Cancer - Dormant Projects (Contd..6), H1 2016 703 Metastatic Colorectal Cancer - Dormant Projects (Contd..7), H1 2016 704 Metastatic Colorectal Cancer - Dormant Projects (Contd..8), H1 2016 705 Metastatic Colorectal Cancer - Discontinued Products, H1 2016 706 Metastatic Colorectal Cancer - Discontinued Products (Contd..1), H1 2016 707 Metastatic Colorectal Cancer - Discontinued Products (Contd..2), H1 2016 708
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
